GSK3A and early-onset autosomal dominant Alzheimer disease: Additionally, we also established that the GSK3α-GSK3β pathway could serve as the potential target for beta-amyloid and tau accumulation characteristically observed in AD condition and OS extract could potentially inactivate this pathway, and hence, serve as a promising treatment for neurodegenerative diseases such as Alzheimer’s disease.